25-27.8.2020 Biointerfaces International 2020, Zurich University of Zurich, where synthetic materials and biological systems interact with and engage each other – one of the most innovative and expanding areas of science and technology over the last two decades.

Related articles

Characterizing Nanopartic... Live Webinar, Thursday 19 November, 15:00 (Zürich). Guest speaker Dr. Sandor Balog, Details, Please register for this event using this link
Swiss NanoConvention 2020
Save the date: NME21 Due to the sanitary situation, Nanomed Europe 21 (NME21) is postponed to Tuesday, September 7 – Thursday, September 9, 2021, still in St. Gallen, Switzerland: Do not miss this
Nanomedicine: The Minuten... Tiny particles that can fight cancer or that can easily pass through any interface within our body are a great promise for medicine. But there is little
Need help with the regist... eREACHNano is a new free web tool focused on helping small and medium-sized companies that may lack sufficient in-house expertise on the regulation covering nanomaterials.
Pigments are Nano A webinar by Nanomaterials are something new and innovative, right? Not necessarily: Certain nanomaterials were already in use in the Stone Age, long before mankind invented
Webinar: Open questions a... Face masks characterize the public spaces today. Together with other measures, such as social distancing, hand hygiene and contact tracing, masks actively contribute to fight the spread
Guidelines: Safe-by-desig... A novel guideline document elaborated by the EU-consortium GoNanoBioMat and presented at the final dissemination event. The GoNanoBioMat framework is designed to elaborate current knowledge to small and medium-sized enterprises
Reliable knowledge on nan... helps with questions about nanomaterials A new contact point for start-ups, SMEs and industry bundles the scientific and regulatory expertise in the field of nanotechnology available
Crucial results for coron... Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen and Director of talks to Empa Quarterly about recent antibody studies, which are